SANA Sana Biotechnology, Inc.

QT17

Latest market price

2.57

-0.15-5.51%

Overview Short InterestFilings

SANAQT17Sana Biotechnology, Inc.·NASDAQ

Overview Short InterestFilings

2.57-5.51%

Loading chart...

Signal & projected range

Short-squeeze setupHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

TRAX-0.33%$45.08 NVAX-3.72%$10.08 NUVB-0.21%$4.76 KLRA-4.10%$12.86 REPL+1.27%$17.61 STOK-0.23%$26.29 QURE-1.86%$24.83 NTLA-5.74%$12.47

Snapshot

Index	—	P/E	—	EPS (ttm)	-0.75	Insider Own	29.37%	Shs Outstand	299.36M	Perf Week	10.30%

Market Cap	769.36M	Forward P/E	—	EPS next Y	-0.59	Insider Trans	0.00%	Shs Float	186.79M	Perf Month	-11.07%

Enterprise Value	668.36M	PEG	—	EPS next Q	-0.15			Short Float	21.87%	Perf Quarter	-19.18%

Income	-212.00M	P/S	—	EPS this Y	—			Short Ratio	12.80	Perf Half Y	-21.41%

Sales	0.00	P/B	4.96	EPS next Y	—	ROA	-49.09%	Short Interest	40.85M	Perf YTD	-36.86%

Book/sh	0.52	P/C	4.81	EPS next 5Y	—	ROE	-134.49%	52W High	5.55 -53.69%	Perf Year	-52.14%

Cash/sh	0.53	P/FCF	—	EPS past 3/5Y	—	ROIC	-64.54%	52W Low	2.22 15.77%	Perf 3Y	-8.54%

Dividend Est.	—	EV/EBITDA	—	Sales past 3/5Y	—	Gross Margin	0.00%	Volatility	6.61% 6.27%	Perf 5Y	-87.19%

Dividend TTM	—	EV/Sales	—	EPS Y/Y TTM	—	Oper. Margin	0.00%	ATR (14)	0.17	Perf 10Y	—

Dividend Ex-Date	—	Quick Ratio	1.38	Sales Y/Y TTM	—	Profit Margin	0.00%	RSI (14)	46.16	Recom	2.18

Dividend Gr. 3/5Y	—	Current Ratio	1.38	EPS Q/Q	43.59%	SMA20	1.78%	Beta	2.29	Target Price	8.50

Payout	0.00%	Debt/Eq	0.38	Sales Q/Q	—	SMA50	-15.52%	Rel Volume	0.65	Prev Close	2.72

Employees	142	LT Debt/Eq	0.38	Earnings	Nov 05	SMA200	-24.26%	Avg Volume	3.21M	Price	2.57

IPO Date	Feb 04, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	-49.76% —	Net Debt/EBITDA	—	Volume	2,075,932	Change	-5.51%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Apr-14-26	Reiterated	Wedbush	Outperform	$7.00
Mar-13-26	Reiterated	Morgan Stanley	Overweight
Mar-04-26	Reiterated	HC Wainwright & Co.	Buy	$8.00 → $7.00
Oct-30-25	Reiterated	JMP Securities	Market Outperform	$5.00 → $8.00
Mar-18-25	Upgrade	Citizens Capital Markets	Market Perform → Market Outperform
Jan-08-25	Upgrade	TD Cowen	Hold → Buy
Nov-05-24	Downgrade	JMP Securities	Market Outperform → Market Perform
Nov-05-24	Reiterated	HC Wainwright & Co.	Buy	$8.00
Jan-16-24	Upgrade	HC Wainwright & Co.	Neutral → Buy

Latest News· Times ET

Oct-13-26

Oct-13-2606:04AM

Sana Biotechnology: A Shot At Diabetesseekingalpha.com

Sep-14-26

Sep-14-2608:41PM

Sana Biotechnology, Inc. (SANA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcriptseekingalpha.com

Sep-10-26

Sep-10-2604:47PM

Sana Biotechnology, Inc. (SANA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcriptseekingalpha.com

10:57AM

Sana Biotechnology, Inc. (SANA) Presents at Wells Fargo 21st Annual Healthcare Conference Transcriptseekingalpha.com

Sep-07-26

Sep-07-2603:09PM

Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?prnewswire.com

Sep-01-26

Sep-01-2604:05PM

Sana Biotechnology to Present at September 2026 Investor Conferencesglobenewswire.com

Aug-14-26

Aug-14-2610:19AM

B of A Securities Maintains Buy on Sana Biotechnology, Lowers Price Target to $6Benzinga

Aug-10-26

Aug-10-2601:06PM

12 Health Care Stocks Moving In Monday's After-Market SessionBenzinga

Jul-30-26

Jul-30-2601:45AM

Sana Biotechnology, Inc. (NASDAQ:SANA) Receives $9.50 Consensus PT from Brokeragesdefenseworld.net

Jul-29-26

Jul-29-2610:09AM

Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?prnewswire.com

Jul-25-26

Jul-25-2602:49AM

Sana Biotechnology: Promising Science, But Dilution Keeps The Rating A HoldSeekingAlpha

Jul-22-26

Jul-22-2604:00AM

Sana Biotechnology: A $1 Billion Market Cap Built On A Pre-Phase 1 FoundationSeekingAlpha

Jul-20-26

Jul-20-2611:51AM

3 Promising Genomics Stocks to Add to Your Portfolio in 2026zacks.com

Jul-15-26

Jul-15-2601:01PM

Sana (SANA) Upgraded to Buy: Here's What You Should Knowzacks.com

Jul-13-26

Jul-13-2608:00AM

Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 Diabetesglobenewswire.com

Company

Sana Biotechnology, Inc. is a biotechnology firm focused on creating treatments using engineered cells. The company develops advanced ex vivo and in vivo cell engineering platforms to address a range of conditions with significant unmet medical needs, including various cancers, diabetes, central nervous system disorders, cardiovascular diseases, and genetic illnesses. Its portfolio of drug candidates includes SG295 and SG242, which are designed to target CD19+ cancer cells involved in non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. For multiple myeloma, Sana is progressing SG221, SG239, and SC255. Other pipeline assets include SG328 for ornithine transcarbamylase deficiency, and SG418 for sickle cell disease and beta-thalassemia. Additionally, the company is advancing SC291, a CD19 allogeneic T cell therapy, SC451 for type I diabetes mellitus, and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Founded in 2018 as FD Therapeutics, Inc., the company adopted its current name, Sana Biotechnology, Inc., in September 2018 and is based in Seattle, Washington.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	0	0	0	0	—	—	—	—	—
Cost of Goods Sold Incl. D&A	2	13	0	0	—	—	—	—	—
Gross Profit	-2	-13	0	0	—	—	—	—	—
Selling, General and Administrative Excl. Other	44	44	64	73	—	—	—	—	—
Research and Development	161	132	209	220	—	—	—	—	—
Other Operating Expense	0	2	0	0	—	—	—	—	—
Operating Income	-208	-191	-273	-293	—	—	—	—	—
Interest Expense	0	0	0	0	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	-4	-53	6	10	—	—	—	—	—
Net Income Before Taxes	-212	-244	-267	-283	—	—	—	—	—
Income Taxes	0	0	0	0	—	—	—	—	—
Consolidated Net Income	-212	-244	-267	-283	—	—	—	—	—
Net Income From Continuing Operations	-212	-244	-267	-283	—	—	—	—	—
Net Income	-212	-244	-267	-283	—	—	—	—	—
EPS (Recurring)	-0.76	-0.96	-1.16	-1.46	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	-0.76	-0.96	-1.16	-1.46	—	—	—	—	—
EPS (Diluted)	-0.75	-0.96	-1.16	-1.46	—	—	—	—	—
EBITDA	-201	-231	-251	-259	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	—	—	—	—	—	—	—	—	—
Gross Margin	—	—	—	—	—	—	—	—	—
Operating Margin	—	—	—	—	—	—	—	—	—
Net Margin	—	—	—	—	—	—	—	—	—
Shares Outstanding	296	253	231	195	—	—	—	—	—
Market Capitalization	761	1,030	377	796	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PATEL DHAVALKUMAR DHIRAJLAL	EVP, Chief Scientific Officer	Aug 26 '26	Option Exercise	0.00	125,000	0	224,510	Aug 27
Harr Steve	President & CEO	Mar 07 '26	Option Exercise	0.00	50,000	0	7,968,596	Mar 10
Wyrick Susan D.	Officer	Mar 07 '26	Option Exercise	0.00	3,250	0	200,583	Mar 10
Harr Steve	President & CEO	Mar 06 '26	Option Exercise	0.00	41,666	0	7,918,596	Mar 10
Wyrick Susan D.	Officer	Mar 06 '26	Option Exercise	0.00	10,416	0	197,333	Mar 10
Wyrick Susan D.	Officer	Mar 02 '26	Option Exercise	0.00	1,525	0	187,408	Mar 04
Wyrick Susan D.	Officer	Jan 02 '26	Option Exercise	0.00	7,500	0	188,290	Jan 06
Wyrick Susan D.	Officer	Dec 13 '25	Option Exercise	0.00	3,400	0	181,663	Dec 16
Wyrick Susan D.	Officer	Dec 03 '25	Option Exercise	0.00	10,000	0	180,828	Dec 05
Wyrick Susan D.	Officer	Jun 03 '25	Option Exercise	0.00	10,000	0	170,395	Dec 05
Cassidy Bernard J	EVP & General Counsel	Mar 07 '25	Option Exercise	0.00	11,041	0	115,823	Mar 10
Wyrick Susan D.	Officer	Mar 07 '25	Option Exercise	0.00	3,250	0	158,231	Mar 10
Harr Steve	President & CEO	Mar 07 '25	Option Exercise	0.00	50,000	0	7,889,750	Mar 10
Wyrick Susan D.	Officer	Mar 02 '25	Option Exercise	0.00	1,525	0	155,471	Mar 03
FMR LLC	10% Owner, See Remark 1	Jan 08 '25	Sale	6.49	290,912	1,887,320	4,541,511	Jan 10

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.